Investment
Features
FeesSafety
Academy
More
Pluang+

Compare BioNTech SE - ADR (BNTX) vs Elastic NV (ESTC) Price & Performance

BioNTech SE - ADRTrade
Elastic NVTrade

Price performance (Past 24H)

Key statistics

BioNTech SE - ADR vs Elastic NV — how do they compare? BioNTech SE - ADR trades at $93.34 (market cap $23.31B), while Elastic NV trades at $77.06 (market cap $7.94B). The key difference: BioNTech SE - ADR is far larger — about 2.9× Elastic NV's market cap, and Elastic NV is trading nearer its 52-week high, BioNTech SE - ADR nearer its low. Which is the better fit depends on your goals.

BNTXESTC
Market Cap
$23.31B$7.94B
Sector
HealthTechnology
52-Week High
$119.34$94.47
52-Week Low
$83.89$43.30
Enterprise Value
$6.60B$7.16B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

BioNTech SE - ADR

BioNTech (BNTX) trades at $93.27, up 0.51% on the day, with a bullish technical signal from moving averages and neutral oscillators. The company reported Q2 2026 revenue of $106 million, missing expectations, and lowered its full-year sales outlook due to weak COVID-19 vaccine demand. Despite negative net income margins and cash outflows, BNTX maintains a strong cash position of $16.78 billion and is advancing its oncology pipeline with 14 pivotal clinical trials.

The outlook is mixed: analyst consensus is strongly bullish with a $121 price target, but declining COVID revenue and ongoing losses pose significant risks. Investment opportunity hinges on successful pipeline development, while near-term headwinds from vaccine demand softness and leadership transition require careful monitoring.

Elastic NV

Elastic (ESTC) trades at $76.64, up 0.42% today, with a bullish technical outlook as it trades above key moving averages. The company reported strong earnings beats in recent quarters, with Q1 2026 EPS of $0.61 exceeding the $0.561 estimate. Recent news highlights include a collaboration with OpenAI and recognition as a leader in Gartner's Magic Quadrant for Observability Platforms. Revenue growth is robust, projected to rise from $1.48B in 2025 to $1.7B in 2026, while net income is expected to turn positive at $368M.

The stock offers growth potential driven by AI partnerships and market leadership, but faces risks from high valuation multiples like a P/E of 22.26 and EV/EBITDA of 206.43. Analyst consensus is bullish with a $74.21 price target and no sell ratings, though RSI levels indicate overbought conditions. Key risks include competitive pressures and reliance on tech sector demand.

Returns comparison

Trailing returns across standard periods

About BioNTech SE - ADR

BioNTech is a Germany-based biotechnology company that focuses on developing cancer therapeutics, including individualized immunotherapy, as well as vaccines for infectious diseases, including COVID-19. The company's oncology pipeline contains several classes of drugs, including mRNA-based drugs to encode antigens, neoantigens, cytokines, and antibodies.

Read more on BNTX

About Elastic NV

Elastic NV provides a leading search AI platform built on Elasticsearch. Its software helps organizations find, observe, and protect data through search-powered analytics for various cloud-based applications.

Read more on ESTC